Search
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexVotucalis
go.drugbank.com/drugs/DB05032InvestigationalIt is a topically delivered small protein that acts as an anti-inflammatory agent.
Amphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalAmphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. … It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted.
Mixtures: Mixed Salts of a Single-Entity Amphetamine Product, Mixed Salts of a Single-Entity Amphetamine ProductOxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitOxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth … Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes.
Benzthiazide
go.drugbank.com/drugs/DB00562ApprovedThiazides also cause loss of potassium and an increase in serum uric acid.
Methionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalA sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Mixtures: AA-Ven, Formula CmSynonyms: L-a-Amino-g-methylthiobutyric acid, MFerric pyrophosphate citrate
go.drugbank.com/drugs/DB13995Approved[A31979] FPC is categorized in Japan as a second class OTC drug. … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.
Ponatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexAtl146e
go.drugbank.com/drugs/DB05191InvestigationalATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Categories: Adenosine A receptor agonists, Adenosine A2 Receptor AgonistsLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].